Emergent BioSolutions has secured around $400 million worth of orders for its smallpox and monkeypox products, including its vaccine being used to help protect against a mpox outbreak in Africa.
The orders are for contracts secured in 2023 and 2024, for vaccines to be delivered this year and next, according to the company. In 2023, Emergent secured a $120 million contract to deliver its smallpox and mpox vaccine ACAM2000 to the US Strategic National Stockpile. And earlier this year it won a government contract worth over $250 million to supply ACAM2000, the immune globulin product CNJ-016, its Anthrax vaccine CYFENDUS and its Botulism vaccine dubbed BAT.
Joe Papa“These incremental orders demonstrate our ongoing leadership to help address serious viral threats like smallpox and mpox,” CEO Joe Papa said in a press release on Wednesday.
As of Wednesday, the vaccine and antibody manufacturer has delivered almost $210 million worth of doses of ACAM2000 for smallpox and mpox and CNJ-016 for complications resulting from smallpox vaccinations. For the rest of the year, it has over $185 million worth of vaccines still to deliver.
Emergent started to assist in the mpox outbreak in August this year, giving away 50,000 doses of ACAM2000 to the Democratic Republic of the Congo, Burundi, Kenya, Rwanda and Uganda. The ACAM2000 vaccine was originally approved only for smallpox, but the FDA updated the approval in August to include mpox, in the same month as the disease was declared a public health emergency by the World Health Organization.